Which hedge funds own NVCT? NUVECTIS PHARMA INC, Q2 2026 13F holders
12 of the hedge funds tracked by WhaleCreep disclosed a position in NVCT (NUVECTIS PHARMA INC) in their Q2 2026 13F filings, worth $78.3m in total. The largest holder by portfolio weight is Iridian Asset Management LLC at 4.9% of its book. 9 managers opened a new position this quarter: Sphera Funds Management Ltd., Soleus Capital Management, L.P., Avidity Partners Management LP, Stonepine Capital Management, LLC. 1 exited: Marshall Wace, LLP.
12tracked managers holding
9opened this quarter
1exited this quarter
Which hedge funds hold NVCT? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Iridian Asset Management LLC | Q2 2026 | 4.9% | $14.3m | 777,078 | 19% | added |
| Occam Crest Management LP | Q2 2026 | 4.1% | $7.4m | 357,147 | -12% | reduced |
| Sphera Funds Management Ltd. | Q2 2026 | 1.0% | $7.0m | 382,945 | – | new |
| Soleus Capital Management, L.P. | Q2 2026 | 0.6% | $18.4m | 1,000,000 | – | new |
| Avidity Partners Management LP | Q2 2026 | 0.6% | $3.7m | 200,000 | – | new |
| Stonepine Capital Management, LLC | Q2 2026 | 0.6% | $735.6k | 40,000 | – | new |
| Perceptive Advisors LLC | Q2 2026 | 0.3% | $18.4m | 1,000,000 | – | new |
| Dafna Capital Management LLC | Q2 2026 | 0.1% | $367.8k | 20,000 | – | new |
| Alyeska Investment Group, L.P. | Q2 2026 | 0.0% | $5.1m | 275,000 | – | new |
| Citadel Advisors LLC | Q2 2026 | 0.0% | $2.1m | 115,532 | 47% | added |
| Schonfeld Strategic Advisors LLC | Q2 2026 | 0.0% | $216.2k | 11,755 | – | new |
| Aqr Capital Management LLC | Q2 2026 | 0.0% | $586.4k | 31,886 | – | new |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Marshall Wace, LLP | 0.0% | $225.9k |
How has hedge fund ownership of NVCT changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 12 | $78.3m |
| Q1 2026 | 4 | $9.0m |
| Q3 2025 | 1 | $257.7k |
| Q2 2025 | 1 | $321.2k |
| Q3 2024 | 1 | $99.4k |
| Q2 2024 | 1 | $471.6k |
| Q1 2024 | 1 | $506.0k |
| Q4 2023 | 1 | $432.0k |
| Q3 2023 | 1 | $327.0k |
| Q2 2023 | 1 | $581.0k |
Counts every tracked manager that disclosed NVCT in that quarter's filing, including managers that have since stopped filing.